# US 2026/0151398 A1 · Compounds for reducing cholesterol and treating liver and kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0151398 A1
- Document ID: US20260151398A1
- Status: Published application
- Kind: A1
- Application number: 18/686,147
- Filed: 2022-08-26
- Published: 2026-06-04
- Earliest claimed: 2021-08-26
- Assignees: McMaster University
- Applicants: McMaster University
- Inventors: Jakob Magolan; Richard Austin; Paul Lebeau; Jae Hyun Byun; Paul Saliba; Matthew Sguazzin
- Web page: https://patentgrep.com/patent/US20260151398A1

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/06: Antihyperlipidemics
- A61P 13/12: of the kidneys
- C07D 473/04: two oxygen atoms
- C07D 473/08: with methyl radicals in positions 1 and 3, e.g. theophylline
- C07D 473/12: with methyl radicals in positions 1, 3, and 7, e.g. caffeine
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This application relates to compounds such as compounds of Formula (I) that block SREBP2-induced hepatic PCSK9 expression, compositions comprising these compounds and methods of use thereof; for example, for treating diseases, disorders or conditions treatable by blocking SREBP2 activation and/or PCSK9 gene expression.

## Claims

### Claim 1

A compound of Formula (Ia):
or a pharmaceutically acceptable salt, solvate and/or prodrug thereof;
wherein
R1 is selected from
(i) phenyl optionally substituted with one to five substituents independently selected from CN, halo, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H and C(O)H, and substituted with one or two of C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(ii) 9-10-membered bicyclic aryl wherein the second ring is phenyl or C5-6cycloalkyl and the 9-10 membered bicyclic aryl is optionally substituted with one or more substituents independently selected from ═O, CN, halo, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(iii) monocyclic C3-6cycloalkyl or C5-6cycloalkenyl optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(iv) 8-10-membered bicyclic cycloalkyl or cycloalkenyl wherein the second ring is C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic cycloalkyl or cycloalkenyl is optionally substituted with one or more substituents independently selected from halo, CN NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(v) monocyclic C5-6heterocycloalkyl optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(vi) 8-10-membered bicyclic heterocycloalkyl wherein the second ring is C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic heterocycloalkyl is optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(vii) monocyclic C5-6heteroaryl, optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2; and
(viii) 8-10-membered bicyclic heteroaryl wherein the second ring C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic heteroaryl is optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
R2 is selected from H, C1-6alkyl and C1-6alkyl substituted with one or more substituents independently selected from OH and halo; and
X1 and X2 are independently selected from O, NH, N(C1-6alkyl), N(C1-6fluoroalkyl), C(O), C(O)O, OC(O), C(O)NH, C(O)N(C1-6alkyl), C(O)N(C1-6fluoroalkyl), NHC(O), N(C1-6alkyl)C(O), N(C1-6fluoroalkyl)C(O), S, S(O) and SO2;
provided that R1 is not:
(a) phenyl monosubstituted with unsubstituted phenyl, unsubstituted pyridinyl and unsubstituted pyrazolyl;
(b) unsubstituted thiophenyl or thiophenyl substituted with Br, NO2, CN, CH3, C(O)H, C(O)CH3 or OCH3;
(c) unsubstituted furanyl or furanyl substituted with Cl, Br, CH3, CF3, C(O)H or phenyl;
(d) unsubstituted pyrimidinyl, unsubstituted pyridinyl or pyridinyl monosubstituted with NHCH3, Br, CH3 or pyridinyl;
(e)
wherein Y is NH, O or S, and when Y is, the phenyl ring is unsubstituted or mono-substituted with OCH3 or Cl; and
(f)

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein X1 is selected from O, C(O), C(O)O, OC(O), C(O)NH, NHC(O) and SO2 and X2 is selected from O and C(O), and R1 is (i) phenyl optionally substituted with one to five substituents independently selected from F, Cl, Br, CN, NH2, OH, NO2, C1-4alkyl, C1-4fluoroalkyl, C1-2alkyleneOH, C1-2alkyleneNH2, C1-2alkyleneNH(C1-6alkyl), C1-2alkyleneN(C1-4alkyl)(C1-4alkyl), O—C1-2alkyl, O—C1-2fluoroalkyl, NHC(O)—C1-2alkyl, NHC(O)C1-4fluoroalkyl, C(O)C1-4alkyl, C(O)C1-4fluoroalkyl C(O)OC1-4alkyl, C(O)OC1-4fluoroalkyl, OC(O)C1-2alkyl, OC(O)C1-4fluoroalkyl, SO2C1-4alkyl, SO2C1-4fluoroalkyl, CO2H, C(O)H, and substituted with one or two of C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, C(O)-phenyl, C1-2alkylene-phenyl, O—C1-2alkylenephenyl, C(O)—C1-2alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 10 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl, C1-4fluoroalkyl, O—C1-4alkyl, O—C1-4fluoroalkyl and NH2.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1 is (i) phenyl substituted with one to four substituents independently selected from F, Cl, Br, CN, NH2, OH, NO2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3, CF2H, CH2CF2H, CH2CF3, CH2CFH2, CH(CF3)2, C(CF3)3, CH(CH3)2O, CH3CH2CH2O, CH3CH2O, CH3O, CF3O, CHF2O, CF2HCH2O, CF3CH2O, (CF3)2CHO, (CF3)3CO, CH2OH, CH2NH2, NHC(O)CH3, NHC(O)CF3, C(O)CH3, C(O)CF3, OC(O)CH3, OC(O)CF3, SO2CH3, SO2CF3, CO2H, C(O)H, and substituted with one or two of C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, C(O)-phenyl, CH2-phenyl, O-CH2phenyl, C(O)—CH2phenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 10 groups being optionally substituted with one or more substituents independently selected from F, Cl, OH, CH3, CF3, CH3O, CF3O, and NH2.

### Claim at position 5

-6. (canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein X1 is O and X2 is O, and R1 is (ii) 9-10-membered bicyclic aryl wherein the second ring is phenyl or C5-6cycloalkyl and the 9-10 membered bicyclic aryl is optionally substituted with one to five substituents independently selected from ═O, halo, CN, NH2, OH, NO2, C1-4alkyl, C1-4fluoroalkyl, C1-2alkyleneOH, C1-2alkyleneNH2, C1-2alkyleneNH(C1-4alkyl), C1-2alkyleneN(C1-4alkyl)(C1-6alkyl), O—C1-4alkyl, O—C1-4fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, C1-4alkylene-phenyl, O—C1-4alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one to five substituents independently selected from halo, OH, C1-4alkyl, C1-4fluoroalkyl, O—C1-4alkyl, O—C1-4fluoroalkyl and NH2.

### Claim at position 7

-11. (canceled)

### Claim 12 (depends on 1)

The compound of claim 1, wherein X1 is O and X2 is O, and R1 is (iii) monocyclic C3-6cycloalkyl or C5-6cycloalkenyl optionally substituted with one to five substituents independently selected from halo, CN, NH2, OH, NO2, C1-4alkyl, C1-4fluoroalkyl, C1-2alkyleneOH, C1-2alkyleneNH2, C1-2alkyleneNH(C1-6alkyl), C1-2alkyleneN(C1-4alkyl)(C1-4alkyl), O—C1-4alkyl, O—C1-4fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, C1-4alkylene-phenyl, O—C1-4alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one to five substituents independently selected from halo, OH, C1-4alkyl, C1-6fluoroalkyl, O—C1-4alkyl, O—C1-4fluoroalkyl and NH2.

### Claim at position 9

-14. (canceled)

### Claim 15 (depends on 1)

The compound of claim 1, wherein X1 is O and X2 is O, and R1 is (iv) 8-10-membered bicyclic cycloalkyl or cycloalkenyl wherein the second ring is C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic cycloalkyl or cycloalkenyl is optionally substituted with one to five substituents independently selected from halo, CN, NH2, OH, NO2, C1-4alkyl, C1-4fluoroalkyl, C1-2alkyleneOH, C1-2alkyleneNH2, C1-2alkyleneNH(C1-6alkyl), C1-2alkyleneN(C1-4alkyl)(C1-4alkyl), O—C1-4alkyl, O—C1-4fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, C1-2alkylene-phenyl, O—C1-4alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one to five substituents independently selected from halo, OH, C1-4alkyl, C1-4fluoroalkyl, O—C1-4alkyl, O—C1-4fluoroalkyl and NH2.

### Claim at position 11

-18. (canceled)

### Claim 19 (depends on 1)

The compound of claim 1, wherein X1 in (v) is O and X2 in (v) is O, and R1 is (v) monocyclic C5-6heterocycloalkyl optionally substituted with one to five substituents independently selected from F, Br, Cl, CN, NH2, OH, NO2, C1-4alkyl, C1-4fluoroalkyl, C1-2alkyleneOH, C1-2alkyleneNH2, C1-4alkyleneNH(C1-4alkyl), C1-4alkyleneN(C1-4alkyl)(C1-4alkyl), O—C1-4alkyl, O—C1-4fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, C1-4alkylene-phenyl, O—C1-2alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one to five substituents independently selected from halo, OH, C1-4alkyl, C1-4fluoroalkyl, O—C1-4alkyl, O—C1-4fluoroalkyl and NH2.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The compound of claim 1, wherein X1 is O and X2 is O, and R1 is (vi) 8-10-membered bicyclic heterocycloalkyl wherein the second ring is C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic heterocycloalkyl is optionally substituted with one to five substituents independently selected from halo, CN, NH2, OH, NO2, C1-4alkyl, C1-4fluoroalkyl, C1-2alkyleneOH, C1-2alkyleneNH2, C1-2alkyleneNH(C1-4alkyl), C1-2alkyleneN(C1-4alkyl)(C1-4alkyl), O—C1-4alkyl, O—C1-4fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, C1-2alkylene-phenyl, O—C1-2alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one to five substituents independently selected from halo, OH, C1-4alkyl, C1-4fluoroalkyl, O—C1-4alkyl, O—C1-4fluoroalkyl and NH2.

### Claim at position 16

-24. (canceled)

### Claim 25 (depends on 1)

The compound of claim 1, wherein X1 in (vii) is selected from O and S and X2 in (vii) is O and R1 is (vi) monocyclic C5-6heteroaryl, optionally substituted with one to five substituents independently selected from halo, CN, NH2, OH, NO2, C1-4alkyl, C1-4fluoroalkyl, C1-2alkyleneOH, C1-2alkyleneNH2, C1-2alkyleneNH(C1-4alkyl), C1-2alkyleneN(C1-4alkyl)(C1-4alkyl), O—C1-4alkyl, S—C1-4alkyl, O—C1-4fluoroalkyl, S—C1-4fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, O-phenyl, C1-2alkylene-phenyl, O—C1-2alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one to five substituents independently selected from halo, OH, C1-4alkyl, C1-4fluoroalkyl, O—C1-4alkyl, O—C1-4fluoroalkyl and NH2.

### Claim at position 18

-27. (canceled)

### Claim 28 (depends on 1)

The compound of claim 1, wherein X1 is selected from O and S and X2 is O and R1 is (viii) 8-10-membered bicyclic heteroaryl wherein the second ring is C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic heteroaryl is optionally substituted with one to five substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-4fluoroalkyl, C1-4alkyleneOH, C1-2alkyleneNH2, C1-2alkyleneNH(C1-4alkyl), C1-2alkyleneN(C1-4alkyl)(C1-4alkyl), O—C1-4alkyl, O—C1-4fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, O-phenyl, C1-2alkylene-phenyl, O—C1-2alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one to five substituents independently selected from halo, OH, C1-4alkyl, C1-4fluoroalkyl, O—C1-4alkyl, O—C1-4fluoroalkyl and NH2.

### Claim at position 20

-30. (canceled)

### Claim 31 (depends on 1)

The compound of claim 1, wherein R2 is selected from H, CH3, CF3, CF2H, CH3O, CF3O, CHF2O and CH2OH.

### Claim 32 (depends on 31)

The compound of claim 31, wherein R2 is H.

### Claim 33

A compound selected from the compounds listed in Table 1 or a pharmaceutically acceptable salt, solvate and/or prodrug thereof.

### Claim 34 (depends on 1)

A pharmaceutical composition comprising one or more compounds of claim 1 or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, and one or more pharmaceutically acceptable carriers.

### Claim 35 (depends on 34)

The composition of claim 34, further comprising one or more cholesterol lowering agents.

### Claim 36

A method of treating a disease, disorder or condition treatable by blocking SREBP2 activation and/or PCSK9 gene expression, the method comprising administering a therapeutically effective amount of one or more compounds of Formula (I), or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, to a subject in need thereof:
wherein
R1 is selected from
(i) phenyl substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(ii) 9-10-membered bicyclic aryl wherein the second ring is phenyl or C5-6cycloalkyl and the 9-10 membered bicyclic aryl is optionally substituted with one or more substituents independently selected from ═O, halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(iii) monocyclic C3-6cycloalkyl or C5-6cycloalkenyl optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(iv) 8-10-membered bicyclic cycloalkyl or cycloalkenyl wherein the second ring is C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic cycloalkyl or cycloalkenyl is optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(v) monocyclic C5-6heterocycloalkyl optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(vi) 8-10-membered bicyclic heterocycloalkyl wherein the second ring is C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic heterocycloalkyl is optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
(vii) monocyclic C5-6heteroaryl, optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2; and
(viii) 8-10-membered bicyclic heteroaryl wherein the second ring is C5-6heterocycloalkyl, phenyl, C5-6cycloalkyl or C5-6heteroaryl and the 8-10-membered bicyclic heteroaryl is optionally substituted with one or more substituents independently selected from halo, CN, NH2, OH, NO2, C1-6alkyl, C1-6fluoroalkyl, C1-6alkyleneOH, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)(C1-6alkyl), X1—C1-6alkyl, X1—C1-6fluoroalkyl, CO2H, C(O)H, C5-6heteroaryl, C5-6heterocycloalkyl, phenyl, X1-phenyl, C1-6alkylene-phenyl, X1—C1-6alkylenephenyl, C3-6cycloalkyl and C3-6cycloalkenyl, the latter 8 groups being optionally substituted with one or more substituents independently selected from halo, OH, C1-6alkyl, C1-6fluoroalkyl, X2—C1-6alkyl, X2—C1-6fluoroalkyl and NH2;
R2 is selected from H, C1-6alkyl and C1-6alkyl substituted with one or more substituents independently selected from OH and halo; and
X1 and X2 are independently selected from O, NH, N(C1-6alkyl), N(C1-6fluoroalkyl), C(O), C(O)O, OC(O), C(O)NH, C(O)N(C1-6alkyl), C(O)N(C1-6fluoroalkyl), NHC(O), N(C1-6alkyl)C(O), N(C1-6fluoroalkyl)C(O), S, S(O) and SO2.

### Claim at position 27

-69. (canceled)

### Claim 70 (depends on 36)

The method of claim 36, wherein the disease, disorder or condition is caused and/or exacerbated by increased SREBP2 and/or PCSK9 function or activity.

### Claim 71 (depends on 36)

The method of claim 36, wherein the disease, disorder or condition is elevated cholesterol levels, liver disease or chronic kidney disease.

### Claim 72 (depends on 36)

The method of claim 36, wherein the therapeutically effective amount of the one or more compounds is administered in combination with one or more other therapeutic agents.

### Claim at position 31

-80. (canceled)

### Claim 81 (depends on 36)

The method of claim 36, wherein the one or more other therapeutic agents is a statin.

### Claim 82

(canceled)
